The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04334629
Recruitment Status : Unknown
Verified May 2020 by King's College London. Recruitment status was: Recruiting
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male or female patients aged 18 years and above;
Confirmed or suspected SARS-CoV-2 infection;
National Early Warning Score (NEWS2) greater than or equal to 3 in a single parameter or NEWS2 > 5 overall;
Acute hypoxemic respiratory failure: PaO2/FiO2 ratio less than or equal to 300 OR SpO2/FiO2 ratio < 315 (Kigali Modification)
Provision of written informed consent by the patient OR by the patient's Legal Representative OR professional consultee.
Any of the following contraindications to ibuprofen:
A known hypersensitivity to ibuprofen or any other constituent of the medicinal product;
Patients who have previously shown hypersensitivity reactions (e.g. asthma, rhinitis, angioedema or urticaria) in response to aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs);
Patients with a history of, or existing gastrointestinal ulceration/perforation or bleeding, including that associated with NSAIDs;
Patients with severe hepatic failure;
Patients with acute renal failure;
Patients with severe heart failure.
Participation in any other investigational drug products less than 30 days prior to study enrolment;
Glasgow Coma Score < 12;
Patients who cannot swallow oral capsules;
Pregnant or lactating women;
Any medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial.